{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T10:31:34Z","timestamp":1789468294496,"version":"build-2803163510"},"reference-count":67,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,3,25]],"date-time":"2025-03-25T00:00:00Z","timestamp":1742860800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neuropharmacology"],"published-print":{"date-parts":[[2025,8]]},"DOI":"10.1016\/j.neuropharm.2025.110428","type":"journal-article","created":{"date-parts":[[2025,3,25]],"date-time":"2025-03-25T23:11:24Z","timestamp":1742944284000},"page":"110428","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"special_numbering":"C","title":["A novel selective phosphodiesterase 9 inhibitor, irsenontrine (E2027), enhances GluA1 phosphorylation in neurons and improves learning and memory via cyclic GMP elevation"],"prefix":"10.1016","volume":"273","author":[{"ORCID":"https:\/\/orcid.org\/0009-0009-2427-7251","authenticated-orcid":false,"given":"Yasuharu","family":"Ishihara","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-8799-9461","authenticated-orcid":false,"given":"Mai","family":"Ando","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasuaki","family":"Goto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-5392-1167","authenticated-orcid":false,"given":"Sadaharu","family":"Kotani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-4786-2539","authenticated-orcid":false,"given":"Naoto","family":"Watanabe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-4070-455X","authenticated-orcid":false,"given":"Yosuke","family":"Nakatani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0116-6275","authenticated-orcid":false,"given":"Satoko","family":"Ishii","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0391-1339","authenticated-orcid":false,"given":"Norimasa","family":"Miyamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8537-951X","authenticated-orcid":false,"given":"Yuji","family":"Mano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yukio","family":"Ishikawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.neuropharm.2025.110428_bib66","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1254\/jjp.54.45","article-title":"A comparison of neurotrophic effects of epidermal growth factor and basic fibroblast growth factor in primary cultured neurons from various regions of fetal rat brain","volume":"54","author":"Abe","year":"1990","journal-title":"Jpn. J. Pharmacol."},{"key":"10.1016\/j.neuropharm.2025.110428_bib1","doi-asserted-by":"crossref","DOI":"10.1177\/2398212820933471","article-title":"Distributed interactive brain circuits for object-in-place memory: a place for time?","volume":"4","author":"Aggleton","year":"2020","journal-title":"Brain Neurosci Adv"},{"issue":"5","key":"10.1016\/j.neuropharm.2025.110428_bib2","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1111\/cns.12688","article-title":"Sildenafil reduces neuroinflammation in cerebellum, restores GABAergic tone, and improves motor in-coordination in rats with hepatic encephalopathy","volume":"23","author":"Agusti","year":"2017","journal-title":"CNS Neurosci. Ther."},{"issue":"22","key":"10.1016\/j.neuropharm.2025.110428_bib3","doi-asserted-by":"crossref","first-page":"9068","DOI":"10.1523\/JNEUROSCI.21-22-09068.2001","article-title":"Expression of cGMP-specific phosphodiesterase 9A mRNA in the rat brain","volume":"21","author":"Andreeva","year":"2001","journal-title":"J. Neurosci."},{"issue":"2","key":"10.1016\/j.neuropharm.2025.110428_bib4","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1007\/s10339-011-0430-z","article-title":"The novel object recognition memory: neurobiology, test procedure, and its modifications","volume":"13","author":"Antunes","year":"2012","journal-title":"Cogn. Process."},{"issue":"3","key":"10.1016\/j.neuropharm.2025.110428_bib5","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1016\/j.nbd.2004.07.022","article-title":"Reduced expression of NO-sensitive guanylyl cyclase in reactive astrocytes of Alzheimer disease, Creutzfeldt-Jakob disease, and multiple sclerosis brains","volume":"17","author":"Baltrons","year":"2004","journal-title":"Neurobiol. Dis."},{"issue":"9","key":"10.1016\/j.neuropharm.2025.110428_bib6","doi-asserted-by":"crossref","first-page":"1158","DOI":"10.1038\/mp.2016.111","article-title":"Reduced pCREB in Alzheimer's disease prefrontal cortex is reflected in peripheral blood mononuclear cells","volume":"21","author":"Bartolotti","year":"2016","journal-title":"Mol. Psychiatr."},{"issue":"3","key":"10.1016\/j.neuropharm.2025.110428_bib7","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1124\/pr.58.3.5","article-title":"Cyclic nucleotide phosphodiesterases: molecular regulation to clinical use","volume":"58","author":"Bender","year":"2006","journal-title":"Pharmacol. Rev."},{"issue":"1","key":"10.1016\/j.neuropharm.2025.110428_bib8","doi-asserted-by":"crossref","DOI":"10.1002\/hup.2569","article-title":"A phase I, randomized, proof-of-clinical-mechanism study assessing the pharmacokinetics and pharmacodynamics of the oral PDE9A inhibitor BI 409306 in healthy male volunteers","volume":"32","author":"Boland","year":"2017","journal-title":"Hum. Psychopharmacol."},{"key":"10.1016\/j.neuropharm.2025.110428_bib9","doi-asserted-by":"crossref","DOI":"10.1016\/0304-3940(95)11323-O","article-title":"Reduced nitric oxide responsive soluble guanylyl cyclase activity in the superior temporal cortex of patients with Alzheimer's disease","volume":"187","author":"Bonkale","year":"1995","journal-title":"Neurosci. Lett."},{"issue":"3","key":"10.1016\/j.neuropharm.2025.110428_bib10","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1016\/0306-4522(95)00349-N","article-title":"Nitric oxide-dependent long-term potentiation is blocked by a specific inhibitor of soluble guanylyl cyclase","volume":"69","author":"Boulton","year":"1995","journal-title":"Neuroscience"},{"issue":"22","key":"10.1016\/j.neuropharm.2025.110428_bib11","doi-asserted-by":"crossref","first-page":"9030","DOI":"10.1073\/pnas.86.22.9030","article-title":"Nitric oxide mediates glutamate-linked enhancement of cGMP levels in the cerebellum","volume":"86","author":"Bredt","year":"1989","journal-title":"Proc. Natl. Acad. Sci. U S A"},{"issue":"Suppl 1","key":"10.1016\/j.neuropharm.2025.110428_bib68","first-page":"S310","article-title":"Role of the brain-derived neurotrophic factor at glutamatergic synapses","volume":"153","author":"Carvalho","year":"2008","journal-title":"Br. J. Pharmacol."},{"issue":"10","key":"10.1016\/j.neuropharm.2025.110428_bib12","doi-asserted-by":"crossref","DOI":"10.3390\/ijms20102450","article-title":"Glial cell AMPA receptors in nervous system Health, injury and disease","volume":"20","author":"Ceprian","year":"2019","journal-title":"Int. J. Mol. Sci."},{"issue":"1","key":"10.1016\/j.neuropharm.2025.110428_bib13","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/S0165-0173(01)00067-4","article-title":"Applications of the Morris water maze in the study of learning and memory","volume":"36","author":"D'Hooge","year":"2001","journal-title":"Brain Res Brain Res Rev"},{"issue":"1","key":"10.1016\/j.neuropharm.2025.110428_bib14","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/S0065-1281(11)80138-8","article-title":"On the stimulation of soluble and particulate guanylate cyclase in the rat brain and the involvement of nitric oxide as studied by cGMP immunocytochemistry","volume":"92","author":"de Vente","year":"1992","journal-title":"Acta Histochem."},{"issue":"1","key":"10.1016\/j.neuropharm.2025.110428_bib15","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1006\/nlme.1999.3919","article-title":"Genetic differences in response to novelty and spatial memory using a two-trial recognition task in mice","volume":"73","author":"Dellu","year":"2000","journal-title":"Neurobiol. Learn. Mem."},{"issue":"4","key":"10.1016\/j.neuropharm.2025.110428_bib16","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1016\/j.neuron.2014.09.024","article-title":"PKA-GluA1 coupling via AKAP5 controls AMPA receptor phosphorylation and cell-surface targeting during bidirectional homeostatic plasticity","volume":"84","author":"Diering","year":"2014","journal-title":"Neuron"},{"issue":"2\u20133","key":"10.1016\/j.neuropharm.2025.110428_bib17","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1007\/s12035-010-8104-x","article-title":"Cyclic GMP and nitric oxide synthase in aging and Alzheimer's disease","volume":"41","author":"Domek-\u0141opaci\u0144ska","year":"2010","journal-title":"Mol. Neurobiol."},{"key":"10.1016\/j.neuropharm.2025.110428_bib18","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1007\/978-3-319-58811-7_9","article-title":"Role of PDE9 in cognition","volume":"17","author":"Dorner-Ciossek","year":"2017","journal-title":"Adv Neurobiol"},{"issue":"5","key":"10.1016\/j.neuropharm.2025.110428_bib19","article-title":"Dynamics of AMPA receptors regulate epileptogenesis in patients with epilepsy","volume":"4","author":"Eiro","year":"2023","journal-title":"Cell Rep Med"},{"issue":"1","key":"10.1016\/j.neuropharm.2025.110428_bib20","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/0166-4328(88)90157-X","article-title":"A new one-trial test for neurobiological studies of memory in rats. 1: behavioral data","volume":"31","author":"Ennaceur","year":"1988","journal-title":"Behav. Brain Res."},{"issue":"1\u20132","key":"10.1016\/j.neuropharm.2025.110428_bib21","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.brainres.2004.12.045","article-title":"Restoration of learning ability in hyperammonemic rats by increasing extracellular cGMP in brain","volume":"1036","author":"Erceg","year":"2005","journal-title":"Brain Res."},{"issue":"25","key":"10.1016\/j.neuropharm.2025.110428_bib22","doi-asserted-by":"crossref","first-page":"15559","DOI":"10.1074\/jbc.273.25.15559","article-title":"Isolation and characterization of PDE9A, a novel human cGMP-specific phosphodiesterase","volume":"273","author":"Fisher","year":"1998","journal-title":"J. Biol. Chem."},{"issue":"1","key":"10.1016\/j.neuropharm.2025.110428_bib23","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1186\/s13195-019-0467-2","article-title":"Evaluation of the efficacy, safety and tolerability of orally administered BI 409306, a novel phosphodiesterase type 9 inhibitor, in two randomised controlled phase II studies in patients with prodromal and mild Alzheimer's disease","volume":"11","author":"Frolich","year":"2019","journal-title":"Alzheimers Res. Ther."},{"issue":"10","key":"10.1016\/j.neuropharm.2025.110428_bib24","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1016\/j.amjmed.2018.01.022","article-title":"Dementia","volume":"131","author":"Gale","year":"2018","journal-title":"Am. J. Med."},{"issue":"11","key":"10.1016\/j.neuropharm.2025.110428_bib25","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1016\/j.tins.2021.08.003","article-title":"Deep entorhinal cortex: from circuit organization to spatial cognition and memory","volume":"44","author":"Gerlei","year":"2021","journal-title":"Trends Neurosci."},{"key":"10.1016\/j.neuropharm.2025.110428_bib26","doi-asserted-by":"crossref","first-page":"837","DOI":"10.3389\/fnins.2019.00837","article-title":"Phosphodiesterase 9A in brain regulates cGMP signaling independent of nitric-oxide","volume":"13","author":"Harms","year":"2019","journal-title":"Front. Neurosci."},{"issue":"1","key":"10.1016\/j.neuropharm.2025.110428_bib27","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1186\/s13195-017-0245-y","article-title":"Reduced cGMP levels in CSF of AD patients correlate with severity of dementia and current depression","volume":"9","author":"Hesse","year":"2017","journal-title":"Alzheimers Res. Ther."},{"issue":"4","key":"10.1016\/j.neuropharm.2025.110428_bib28","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1016\/j.neuropharm.2011.05.009","volume":"61","author":"Hutson","year":"2011","journal-title":"Neuropharmacology"},{"issue":"17","key":"10.1016\/j.neuropharm.2025.110428_bib29","doi-asserted-by":"crossref","first-page":"3030","DOI":"10.1002\/anie.200802808","article-title":"Alzheimer's disease: from pathology to therapeutic approaches","volume":"48","author":"Jakob-Roetne","year":"2009","journal-title":"Angew Chem. Int. Ed. Engl."},{"issue":"1","key":"10.1016\/j.neuropharm.2025.110428_bib30","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1186\/s12967-023-04368-0","article-title":"Phosphodiesterase and psychiatric disorders: a two-sample Mendelian randomization study","volume":"21","author":"Jiang","year":"2023","journal-title":"J. Transl. Med."},{"issue":"5","key":"10.1016\/j.neuropharm.2025.110428_bib31","doi-asserted-by":"crossref","first-page":"3240","DOI":"10.1093\/nar\/gks1227","article-title":"CREB regulates the expression of neuronal glucose transporter 3: a possible mechanism related to impaired brain glucose uptake in Alzheimer's disease","volume":"41","author":"Jin","year":"2013","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/j.neuropharm.2025.110428_bib32","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/j.cellsig.2017.11.004","article-title":"Cyclic nucleotide signaling changes associated with normal aging and age-related diseases of the brain","volume":"42","author":"Kelly","year":"2018","journal-title":"Cell. Signal."},{"issue":"2","key":"10.1016\/j.neuropharm.2025.110428_bib33","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/0166-4328(83)90050-5","article-title":"Long-term memory for contextual attributes: dissociation of amygdala and hippocampus","volume":"8","author":"Kesner","year":"1983","journal-title":"Behav. Brain Res."},{"issue":"7","key":"10.1016\/j.neuropharm.2025.110428_bib34","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pbio.1001900","article-title":"Calcineurin mediates synaptic scaling via synaptic trafficking of Ca2+-permeable AMPA receptors","volume":"12","author":"Kim","year":"2014","journal-title":"PLoS Biol."},{"issue":"2","key":"10.1016\/j.neuropharm.2025.110428_bib35","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1124\/jpet.111.191353","article-title":"Phosphodiesterase 9A regulates central cGMP and modulates responses to cholinergic and monoaminergic perturbation in vivo","volume":"341","author":"Kleiman","year":"2012","journal-title":"J. Pharmacol. Exp. Therapeut."},{"issue":"9","key":"10.1016\/j.neuropharm.2025.110428_bib36","doi-asserted-by":"crossref","first-page":"2072","DOI":"10.1016\/j.neurobiolaging.2014.03.023","article-title":"PDE9A inhibition rescues amyloid beta-induced deficits in synaptic plasticity and cognition","volume":"35","author":"Kroker","year":"2014","journal-title":"Neurobiol. Aging"},{"issue":"6","key":"10.1016\/j.neuropharm.2025.110428_bib37","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1016\/j.neuropharm.2010.05.004","article-title":"Quantitative comparison of phosphodiesterase mRNA distribution in human brain and peripheral tissues","volume":"59","author":"Lakics","year":"2010","journal-title":"Neuropharmacology"},{"issue":"1","key":"10.1016\/j.neuropharm.2025.110428_bib38","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/S0149-7634(01)00041-0","article-title":"The neurobiological basis of spontaneous alternation","volume":"26","author":"Lalonde","year":"2002","journal-title":"Neurosci. Biobehav. Rev."},{"issue":"3","key":"10.1016\/j.neuropharm.2025.110428_bib39","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1097\/WAD.0000000000000515","article-title":"Phase 1 single ascending and multiple ascending dose studies of phosphodiesterase-9 inhibitor E2027: confirmation of target engagement and selection of phase 2 dose in dementia with Lewy bodies trial","volume":"36","author":"Landry","year":"2022","journal-title":"Alzheimer Dis. Assoc. Disord."},{"key":"10.1016\/j.neuropharm.2025.110428_bib40","doi-asserted-by":"crossref","DOI":"10.1016\/j.pbb.2021.173273","article-title":"Object recognition and Morris water maze to detect cognitive impairment from mild hippocampal damage in rats: a reflection based on the literature and experience","volume":"210","author":"Lissner","year":"2021","journal-title":"Pharmacol. Biochem. Behav."},{"key":"10.1016\/j.neuropharm.2025.110428_bib41","article-title":"Novel object recognition test for the investigation of learning and memory in mice","volume":"126","author":"Lueptow","year":"2017","journal-title":"J. Vis. Exp."},{"issue":"4","key":"10.1016\/j.neuropharm.2025.110428_bib42","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1007\/s000180050312","article-title":"Protein kinases: which one is the memory molecule?","volume":"55","author":"Micheau","year":"1999","journal-title":"Cell. Mol. Life Sci."},{"issue":"1","key":"10.1016\/j.neuropharm.2025.110428_bib43","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1007\/s11011-010-9184-z","article-title":"Cyclic GMP pathways in hepatic encephalopathy. Neurological and therapeutic implications","volume":"25","author":"Montoliu","year":"2010","journal-title":"Metab. Brain Dis."},{"issue":"3","key":"10.1016\/j.neuropharm.2025.110428_bib44","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/S1537-1891(03)00049-1","article-title":"The enhanced NO-induced cGMP response induced by long-term L-NAME treatment is not due to enhanced expression of NO-sensitive guanylyl cyclase","volume":"40","author":"M\u00fcllershausen","year":"2003","journal-title":"Vasc. Pharmacol."},{"issue":"6","key":"10.1016\/j.neuropharm.2025.110428_bib45","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1016\/0031-9384(87)90286-1","article-title":"The radial arm maze as a tool in behavioral pharmacology","volume":"40","author":"Olton","year":"1987","journal-title":"Physiol. Behav."},{"issue":"2\u20133","key":"10.1016\/j.neuropharm.2025.110428_bib46","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/S0014-2999(97)01301-0","article-title":"Possible role of nitric oxide-cyclic GMP pathway in object recognition memory: effects of 7-nitroindazole and zaprinast","volume":"337","author":"Prickaerts","year":"1997","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.neuropharm.2025.110428_bib47","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1186\/1750-1326-6-60","article-title":"Downregulation of CREB expression in Alzheimer's brain and in A\u03b2-treated rat hippocampal neurons","volume":"6","author":"Pugazhenthi","year":"2011","journal-title":"Mol. Neurodegener."},{"key":"10.1016\/j.neuropharm.2025.110428_bib48","doi-asserted-by":"crossref","DOI":"10.1186\/1750-1326-6-60","article-title":"Downregulation of CREB expression in Alzheimer's brain and in A\u03b2-treated rat hippocampal neurons","volume":"6","author":"Pugazhenthi","year":"2011","journal-title":"Mol. Neurodegener."},{"key":"10.1016\/j.neuropharm.2025.110428_bib49","doi-asserted-by":"crossref","first-page":"8","DOI":"10.3389\/fnsyn.2020.00008","article-title":"Phosphorylation-dependent regulation of Ca(2+)-permeable AMPA receptors during hippocampal synaptic plasticity","volume":"12","author":"Purkey","year":"2020","journal-title":"Front. Synaptic Neurosci."},{"issue":"11","key":"10.1016\/j.neuropharm.2025.110428_bib50","doi-asserted-by":"crossref","first-page":"3332","DOI":"10.1111\/j.1460-9568.2007.05589.x","article-title":"Expression of the cGMP-specific phosphodiesterases 2 and 9 in normal and Alzheimer\u2019s disease human brains","volume":"25","author":"Reyes-Irisarri","year":"2007","journal-title":"Eur. J. Neurosci."},{"issue":"3","key":"10.1016\/j.neuropharm.2025.110428_bib51","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1124\/jpet.119.260059","article-title":"The novel phosphodiesterase 9A inhibitor BI 409306 increases cyclic guanosine monophosphate levels in the brain, promotes synaptic plasticity, and enhances memory function in rodents","volume":"371","author":"Rosenbrock","year":"2019","journal-title":"J. Pharmacol. Exp. Therapeut."},{"issue":"5","key":"10.1016\/j.neuropharm.2025.110428_bib52","doi-asserted-by":"crossref","first-page":"413","DOI":"10.2174\/1567205011666140505100858","article-title":"A multicenter, double-blind, placebo-controlled trial of the PDE9A inhibitor, PF-04447943, in Alzheimer's disease","volume":"11","author":"Schwam","year":"2014","journal-title":"Curr. Alzheimer Res."},{"issue":"6667","key":"10.1016\/j.neuropharm.2025.110428_bib53","doi-asserted-by":"crossref","DOI":"10.1126\/science.add7046","article-title":"Transcriptomic diversity of cell types across the adult human brain","volume":"382","author":"Siletti","year":"2023","journal-title":"Science"},{"issue":"1","key":"10.1016\/j.neuropharm.2025.110428_bib54","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1007\/s41105-021-00349-2","article-title":"Genome-wide association study of idiopathic hypersomnia in a Japanese population","volume":"20","author":"Tanida","year":"2022","journal-title":"Sleep Biol. Rhythm"},{"issue":"15","key":"10.1016\/j.neuropharm.2025.110428_bib55","doi-asserted-by":"crossref","first-page":"4103","DOI":"10.1523\/JNEUROSCI.3451-16.2017","article-title":"Functional connectivity of multiple brain regions required for the consolidation of social recognition memory","volume":"37","author":"Tanimizu","year":"2017","journal-title":"J. Neurosci."},{"issue":"2","key":"10.1016\/j.neuropharm.2025.110428_bib56","doi-asserted-by":"crossref","first-page":"171","DOI":"10.2174\/1567205053585945","article-title":"Nitric oxide mimetic molecules as therapeutic agents in Alzheimer's disease","volume":"2","author":"Thatcher","year":"2005","journal-title":"Curr. Alzheimer Res."},{"issue":"49","key":"10.1016\/j.neuropharm.2025.110428_bib57","doi-asserted-by":"crossref","first-page":"35297","DOI":"10.1074\/jbc.M113.516690","article-title":"Ca2+-permeable AMPA (alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid) receptors and dopamine D1 receptors regulate GluA1 trafficking in striatal neurons","volume":"288","author":"Tukey","year":"2013","journal-title":"J. Biol. Chem."},{"issue":"1","key":"10.1016\/j.neuropharm.2025.110428_bib58","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/0022-510X(94)90236-4","article-title":"Impairment in the acquisition of passive and active avoidance learning tasks due to bilateral entorhinal cortex lesions","volume":"125","author":"Ueki","year":"1994","journal-title":"J. Neurol. Sci."},{"issue":"4","key":"10.1016\/j.neuropharm.2025.110428_bib59","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1111\/nan.12203","article-title":"Decreased levels of guanosine 3', 5'-monophosphate (cGMP) in cerebrospinal fluid (CSF) are associated with cognitive decline and amyloid pathology in Alzheimer's disease","volume":"41","author":"Ugarte","year":"2015","journal-title":"Neuropathol. Appl. Neurobiol."},{"issue":"5","key":"10.1016\/j.neuropharm.2025.110428_bib60","doi-asserted-by":"crossref","first-page":"908","DOI":"10.1016\/j.neuropharm.2008.07.005","article-title":"The novel selective PDE9 inhibitor BAY 73-6691 improves learning and memory in rodents","volume":"55","author":"van der Staay","year":"2008","journal-title":"Neuropharmacology"},{"issue":"4","key":"10.1016\/j.neuropharm.2025.110428_bib61","doi-asserted-by":"crossref","first-page":"120","DOI":"10.3109\/01677063.2011.630494","article-title":"The selective phosphodiesterase 9 (PDE9) inhibitor PF-04447943 attenuates a scopolamine-induced deficit in a novel rodent attention task","volume":"25","author":"Vardigan","year":"2011","journal-title":"J. Neurogenet."},{"issue":"3","key":"10.1016\/j.neuropharm.2025.110428_bib62","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/S0197-4580(99)00035-4","article-title":"Phenotypic down-regulation of glutamate receptor subunit GluR1 in Alzheimer's disease","volume":"20","author":"Wakabayashi","year":"1999","journal-title":"Neurobiol. Aging"},{"issue":"41","key":"10.1016\/j.neuropharm.2025.110428_bib63","doi-asserted-by":"crossref","first-page":"15124","DOI":"10.1073\/pnas.0602795103","article-title":"Phosphodiesterase genes are associated with susceptibility to major depression and antidepressant treatment response","volume":"103","author":"Wong","year":"2006","journal-title":"Proc Natl Acad Sci U. S. A."},{"issue":"6","key":"10.1016\/j.neuropharm.2025.110428_bib64","doi-asserted-by":"crossref","first-page":"1775","DOI":"10.1124\/mol.105.017608","article-title":"Characterization of the first potent and selective PDE9 inhibitor using a cGMP reporter cell line","volume":"68","author":"Wunder","year":"2005","journal-title":"Mol. Pharmacol."},{"issue":"1\u20132","key":"10.1016\/j.neuropharm.2025.110428_bib65","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/0006-8993(95)00178-S","article-title":"Reduction of AMPA-selective glutamate receptor subunits in the entorhinal cortex of patients with Alzheimer's disease pathology: a biochemical study","volume":"678","author":"Yasuda","year":"1995","journal-title":"Brain Res."}],"container-title":["Neuropharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0028390825001340?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0028390825001340?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,7]],"date-time":"2026-05-07T08:33:42Z","timestamp":1778142822000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0028390825001340"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8]]},"references-count":67,"alternative-id":["S0028390825001340"],"URL":"https:\/\/doi.org\/10.1016\/j.neuropharm.2025.110428","relation":{},"ISSN":["0028-3908"],"issn-type":[{"value":"0028-3908","type":"print"}],"subject":[],"published":{"date-parts":[[2025,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A novel selective phosphodiesterase 9 inhibitor, irsenontrine (E2027), enhances GluA1 phosphorylation in neurons and improves learning and memory via cyclic GMP elevation","name":"articletitle","label":"Article Title"},{"value":"Neuropharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.neuropharm.2025.110428","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"110428"}}